Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganitumab + rilotumumab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination of two fully human monoclonal antibodies for oncology research: ganitumab is an anti–insulin-like growth factor 1 receptor (IGF1R) antibody that blocks IGF-1/IGF-2 signaling, and rilotumumab is an anti–hepatocyte growth factor (HGF) antibody that inhibits HGF binding to the MET receptor. Evaluated primarily in combination regimens (e.g., with panitumumab or platinum–etoposide) for metastatic colorectal cancer and extensive-stage small-cell lung cancer; clinical studies did not demonstrate clear improvement in overall outcomes versus comparators, though safety was generally tolerable in tested regimens.[2][1][3]
- Other names
- ganitumab and rilotumumab
02
Targets
HGF (Hepatocyte growth factor)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on ganitumab + rilotumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganitumab + rilotumumab.